BCOP Self-Study

BCOP Self Study 2022: Lessons Learned From Recent Pediatric Leukemia Trials (Release II)

On-demand Leukemia accounts for approximately 30% of malignancies in children and young adults. It is relatively uncommon for new drug development to focus on pediatric malignancies, therefore advances in pediatric leukemia treatment often come from multicenter phase 3 trials using commercially available medications. Learn more

BCOP Self Study 2022: Detonate What You Knew About Localized Rectal Cancer: Total Neoadjuvant Treatment (TNT) is Exploding (Release II)

On-demand Due to advancements in clinical staging technologies, surgical techniques, and radiation methods, treatment of localized rectal cancer has evolved to a multidisciplinary approach Learn more

BCOP Self Study 2022: Chronic Graft-Versus-Host Disease Updates in Systemic Therapy (Release II)

On-demand This session will highlight literature updates in chronic graft-versus-host disease (cGVHD). cGVHD is a challenging disease and increases morbidity and mortality in patients post allogeneic hematopoietic cell transplantation (HCT). Learn more

2022 BCOP Self Study: Oncology Drug Approval Process (Release I)

On-demand This module’s goal is to review the oncology drug approval process including expedited approval programs and potential obstacles with these programs. Learn more

2021 BCOP Self-Study: New Agents in the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Release II)

On-demand This module will evaluate the data supporting the use of selected novel agents. The role of CAR-T therapy will be covered in a future module. Learn more

2021 BCOP Self-Study: Updates in the Systemic Treatment of Advanced Biliary Tract Cancer (Release II)

On-demand In this module, participants will examine the risks and benefits of recent triple-drug chemotherapy for advanced biliary tract cancers, explore the role of targeted agents for advanced cholangiocarcinoma, and consider the unique toxicity profile of FGFR-inhibitor therapy. Learn more

2021 BCOP Self-Study: Utilization of Novel Therapeutics in the Management of Relapsed and Refractory Multiple Myeloma (Release II)

On-demand In this module, participants will review recent FDA approvals in the management of RRMM, including management of triple-class refractory disease. Novel mechanistic strategies, including modulators of nuclear export (selinexor), enhanced alkylators (melphalan flufenamide), and B-cell maturation antigen (BMCA) targeted agents (belantamab mafadotin and idecabtagene vicelucel) will be discussed. Participants will also review management strategies for unique therapy-related toxicity, notably ocular toxicity associated with belantamab mafadotin. Learn more

2021 BCOP Self-Study: Updates in Metastatic Bladder Cancer (Release II)

On-demand This module highlights new literature and guideline updates in locally advanced and metastatic bladder cancer, including a review of targeted treatments with novel mechanisms and immunotherapy maintenance in the frontline setting. Learn more

2022 BCOP Self Study: Non-Small-Cell Lung Cancer (NSCLC): Novel Pharmacology (Release I)

On-demand The purpose of this module is to review mechanisms of EGFR resistance to third-generation EGFR TKIs, explore novel targets and methods of overcoming these resistance pathways, and examine new drugs recently approved and under investigation. Learn more

2022 BCOP Self Study: Putting the PRO in Professional Cancer Care Use of Patient Reported Outcomes in Oncology (Release I)

On-demand Throughout this module participants will explore the challenges of incorporating PROs in clinical research and how to interpret results in the context of literature analysis Learn more

2021 BCOP Self-Study: Precision Medicine in Oncology (Release II)

On-demand In this module, participants will review advances in precision medicine including novel clinical trial design. Participants will also review the strengths and weaknesses of these novel trial designs, challenges with applying for precision medicine, and recent clinic outcomes in trials utilizing precision medicine for patients with non-small cell lung cancer (NSCLC). Learn more

2022 BCOP Self Study: Paroxysmal Nocturnal Hemoglobinuria (Release I)

On-demand This session will review therapeutic efficacy of complement inhibitors in paroxysmal nocturnal hemoglobinuria (PNH). This session will review recent product approvals and supporting literature to help the pharmacist best determine the rationale for product selection in this rare disease state. Learn more

2022 BCOP Self Study: Updates in the Treatment of Castration-Resistent Prostate Cancer, Precision Medicine Focus (Release I)

On-demand In this module, participants will review developments in the management of CRPC including emerging therapies that may further change the treatment landscape of prostate cancer. Learn more

2021 BCOP Self Study Release I+II (Bundle)

On-demand The 2021 Self-Study Release I and Release II modules feature cutting-edge discoveries from primary oncology literature published within the last 2 years. Emphasis is placed on case-based application of the readings and content outlines. BCOP Self-Study Modules are on-demand and allow you to review and complete at your convenience for up to one year following the release of the education. Learn more

2022 BCOP Self Study Release I (Bundle)

On-demand The 2022 BCOP Self-Study Release I features cutting-edge discoveries from primary oncology literature recently published. Emphasis is placed on case-based application of the readings and content outlines. BCOP Self-Study modules are on-demand and allow you to review and complete at your convenience for up to one year following the release of the education. Learn more

2021 BCOP Self Study Release II (Bundle)

On-demand The 2021 Self-Study Release II features cutting-edge discoveries from primary oncology literature published within the last 2 years. Emphasis is placed on case-based application of the readings and content outlines. BCOP Self-Study modules are on-demand and allow you to review and complete at your convenience for up to one year following the release of the education. Learn more